HIV-Specific Neutralizing Antibodies by Target

A number of broadly neutralizing antibodies that target various regions of HIV’s Env protein are being developed for HIV prevention.

Broadly Neutralizing Antibody Combinations

Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.

ARV-Based and Multipurpose Prevention Technology R&D Pipeline

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Click here for a view of all large-scale prevention trials.

Avac Event

The Future of HIV Prevention: A People’s Research Agenda for Speed, Scale and Equity

First developed in 2024 in partnership with global advocates and communities, the People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. The PRA tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations.

  • Featured speaker Jeanne Marrazzo, former Director of the National Institute of Allergy and Infectious Diseases and AVAC board member.
  • We will cover what the People’s Research Agenda tracks, why it matters, and the advocacy priorities that will shape the future of prevention R&D.

Moving a Product to the Real World

The rollout of oral PrEP demonstrates that people don’t take PrEP simply because it’s available—there needs to be a demand for it, and it needs to be accessible, acceptable and used effectively by those who need and want it. These are the lessons the field is applying to the rollout of the dapivirine vaginal ring (DVR), and injectable cabotegravir (CAB) and lenacapavir (LEN) for PrEP. To reach the UNAIDS target of 10 million PrEP users by 2025, initiations of oral PrEP alone will not be enough—and this graphic shows that the field is beginning to apply past lessons to accelerate introduction of injectable PrEP options.

And for the latest on lenacapavir, visit here.

Preparing for LEN

Learning Lessons, Accelerating Access, Reducing Time to Impact

In the first year since efficacy results were reported, LEN for PrEP has achieved critical milestones in record time compared to oral PrEP, the dapivirine vaginal ring, and injectable cabotegravir. Speed, scale, and equity are still needed to deliver impact.

View the interactive version on our comprehensive page on all things lenacapavir. And the animated GIF version is available for download.

HIV Prevention R&D at Risk

Tracking the Impact of US Funding Cuts

The US presidential administration is actively working to dismantle HIV research and demolish the architecture of global health. The entire HIV response — from basic research and clinical development to policy, programs, and global access to life-saving treatment and prevention — is now under attack, and the world runs the risk of reversing the strides made to end HIV.

AVAC has put together this report, highlighting the impact of US cuts on the pipeline of HIV prevention research and development. AVAC will continue to track these cuts and their impact, to amplify the damage they will cause, and to fight for their reversal.

Download

Avac Event

The Quest For An HIV Cure — Will It Be Discovered in Africa?

We explored what has been happening in terms of HIV cure research in Africa, and discussed opportunities to support more Africa-focused HIV cure research.

Moderator:
Anna Miti, The Choice Agenda

Speakers:

  • Dr. Thumbi Ndung’u, Africa Health Research Institute
  • Dr. Gabriela Cromhout, University of KwaZulu-Natal
  • Adaobi Lisa Olisa, Root to Rise, IAS HIV Vaccine & Cure Advocacy Fellow

Recording / Transcript / Slides / Resources

An Overview of Lenacapavir for PrEP Trials

The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1 and PURPOSE 2.

The HIV Prevention Pipeline

This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.